Vice Dean for Clinical Research
School of Medicine
Medical Director, Center for Clinical Research
Director, UCI Alpha Stem Cell Clinic, Sue and Bill Gross Stem Cell Research Center
School of Medicine
M.D., Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, 1997
Ph.D., University of Southern California, 2003, Molecular Biology
United Council for Neurologic Subspecialties, 2011, Neuro-Oncology
Phone: (714) 456-7214
Fax: (714) 456-6894
University of California, Irvine
University of California, Irvine - School of Medicine
1001 Health Sciences Road
252 Irvine Hall, Suite 222D
Irvine, CA 92697
Physician of Excellence, OCMA: 2020, 2019, 2016
Top Doctors,OC Physicians, As Among the Most Accomplished & Caring, Orange Coast Magazine 2019
ARIISE Awards 2018
Physician of Excellence Award, Orange Coast Magazine, 2017
GBM's Hero's Novocure, 2016
UCI Dean's Physicvian Award 2014
UCI Exceptional Communicator Award 2014
UCI NCI Clinician Award 2012
UCI Stewardship Stard Award 2011, 2010
National Association of Women Business Owners Award 20090
Daniela Bota, MD, PhD is the Vice Dean for Clinical Research and Medical Director for the UCI Center for Clinical Research. She also serves as the Clinical Director for the Sue & Bill Gross Stem Cell Research Center.
Dr. Bota leads the Center for Clinical Research (CCR), UCI’s leading-edge clinical research program dedicated to innovating, accelerating, growing and inspiring new ways to address and treat disease. CCR functions as a full-service clinical research unit, connecting the academic and industry partners with UCI physician and scientists, and enabling the development of novel treatments for our local, regional, national and international patients.
Dr. Bota’s academic research and clinical practice focuses on the innovative treatments for brain malignancies. She currently serves as a principal investigator for numerous studies including novel glioblastoma stem-cell targeted chemotherapy agents, cellular immunotherapy studies, and wearable devices. She consults for multiple companies involved in developing drugs, cellular therapies and devices for human use.
DA Bota, RM Dafer. Acute Methotrexate Neurotoxicity with Choreiform Movements and Focal Neurological Deficits : A Case Report. South Med J. 2009 102 (10):1071-1074
RG Bota, K. Sagduyu, EE Filin, DA Bota, JS Munro. Toward a Better Identificatiuon and Treatment of Schizophrenia Prodrome. The Bulletin of the Menninger Clinic. 72(3):210-227 2008.
Daniela A Bota, Henry S. Friedman Interstitial Chemotherapy with Biodegradable BCNU (Gliadel) Wafers in the Treatment of Malignant Gliomas Therapeutics and Clinical Risk Management, 3(5): 707-715. 2007
D. A. Bota, MD, PhD; G. Gronseth, MD; M. Glantz, MD. Practice Parameter: Radiation therapy and Chemotherapy for Low-Grade Glioma (An Evidence-Based Review). Report of the Quality Standards Subcommittee of the American Academy of Neurology (accepted for publication)
Bota RG, M.D., Munro JS, M.D., Ricci WF, M.D., Bota DA, M.D., Ph.D. “Dynamics of insight in the prodrome of schizophrenia” CNS Spectrum 11(5):355-62. 2006
Bota, D.A., Ngo, J.K., and Davies, K.J.A., 2005. Downregulation of the Human Lon Protease Impairs Mitochondrial Structure, Function and Replication, and Causes Cell Death. Free Radic. Biol. Med. 38, 665-77
Bota, D.A., and Davies, K.J.A., 2002. Lon protease preferentially degrades oxidized mitochondrial aconitase by an ATP-stimulated mechanism. Nature Cell Biology 4, 674-680.
Bota, D.A., Van Remmen, H. and Davies, K.J.A., 2002. Modulation of Lon Protease Activity and Aconitase Turnover during Aging and Oxidative Stress. FEBS Letters 532, 103-106.
Bota, D.A., 2002. Importance of the Lon protease in Mitochondrial Protein Turnover and Cellular Bioenergetics during Oxidative Stress and Aging. PhD Dissertation Defense, University of Southern California, Department of Molecular and Computational Biology
Bota, D. A., and Davies, K.J.A., 2001. Protein Degradation in Mitochondria: Implications for Oxidative Stress, Aging and Disease. A novel etiological classification of mitochondrial proteolysis disorders. Mitochondrion 1, 33-49.
ASC Seed Award
National Institutes of Health (NIH), "The Mechanisms of Chemotherapy Induced Cognitive Defects" 2011-2012
Society of Neuro-Oncology
American Society of Clinical Oncology
American Academy of Neurology
American Medical Association
American Association of Cancer Research
American Association of Neurological Surgeons & the Congress of Neurological Surgeons
Medical Oncology Association of Southern California
Romanian Society of Oncology
National Federation of Aging Research – Glenn/AFAR Fellow
Society for Immunotherapy of Cancer